GO:0097497 blood vessel endothelial cell delamination: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097497 describes the negative regulation of cell adhesion that causes blood vessel endothelial cells to split off from an existing endothelial sheet.
• Endothelial delamination is a normal developmental and homeostatic process, but it also contributes to pathological vascular remodeling and endothelial-to-mesenchymal transition (EndMT) [1,3].
• Key molecular players include adhesion molecules (VE-cadherin, N-cadherin), cytoskeletal regulators (Rho GTPases, actin-binding proteins), and transcription factors (Snail, Slug, Twist) that drive junctional disassembly [1,3].
• Delamination can be studied using organ-on-a-chip models, live imaging of zebrafish and mouse vessels, and genetic lineage tracing [4,5,7].
• Dysregulated delamination is implicated in atherosclerosis, cancer progression, and fibrotic diseases, making it a target for therapeutic intervention [1,3].
• CRISPR-based knockout, knock-in, and overexpression models enable precise dissection of genes controlling endothelial delamination [4,7].
Description
Blood vessel endothelial cell delamination (GO:0097497) is a biological process defined as the negative regulation of cell adhesion that results in blood vessel endothelial cells splitting off from an existing endothelial sheet. This process is essential for vascular development, remodeling, and homeostasis, allowing endothelial cells to detach from the vessel wall and migrate to form new vessels or contribute to other tissues [4,7]. Delamination is distinct from apoptosis or cell death; it is an active, adhesion-dependent event that requires coordinated changes in cell-cell and cell-matrix interactions [1,3]. In recent years, endothelial delamination has gained attention as a key step in both physiological and pathological angiogenesis. For example, during intussusceptive angiogenesis, endothelial cells delaminate to form transluminal bridges, a process visualized in organ-on-a-chip models. In disease, aberrant delamination contributes to endothelial-to-mesenchymal transition (EndMT), a hallmark of atherosclerosis and fibrosis [1,3]. Understanding the molecular regulation of delamination is therefore critical for developing therapies that target vascular remodeling. This article synthesizes current knowledge on GO:0097497, covering its definition, molecular mechanisms, key genes, disease relevance, and state-of-the-art research methods including CRISPR-based models. All statements are supported by peer-reviewed literature to ensure accuracy and reproducibility.
blood vessel endothelial cell delamination At A Glance
| GO ID | GO:0097497 |
|---|---|
| GO term | blood vessel endothelial cell delamination |
| Ontology | biological_process |
| Synonym | none |
| Major function | Negative regulation of cell adhesion leading to endothelial cell detachment from an existing sheet |
| Related processes | Angiogenesis, endothelial-to-mesenchymal transition (EndMT), vascular remodeling |
| Cellular location | Endothelial cell junctions, actin cytoskeleton, extracellular matrix |
| Key regulators | Adhesion molecules (VE-cadherin, N-cadherin), Rho GTPases, transcription factors (Snail, Slug, Twist) |
What Is GO:0097497?
According to the Gene Ontology, GO:0097497 (blood vessel endothelial cell delamination) is the process of negative regulation of cell adhesion that results in blood vessel endothelial cells splitting off from an existing endothelial sheet. In simpler terms, it is the controlled detachment of endothelial cells from the inner lining of blood vessels, allowing them to leave the vessel wall and participate in new vessel formation or tissue remodeling.
Why Is blood vessel endothelial cell delamination Important in Cell Biology?
Blood vessel endothelial cell delamination is fundamental to vascular biology because it governs how endothelial cells exit the vessel wall to form new capillaries, repair injured vessels, and contribute to organ development. Dysregulation of this process is linked to major human diseases, including atherosclerosis, cancer, and fibrosis, where excessive or insufficient delamination disrupts vascular integrity and promotes pathology [1,3]. Studying GO:0097497 provides insights into the molecular switches that control endothelial plasticity and offers potential targets for therapeutic intervention.
• Essential for developmental angiogenesis and vascular remodeling.
• Drives intussusceptive angiogenesis by forming transluminal bridges.
• Contributes to endothelial-to-mesenchymal transition (EndMT) in atherosclerosis.
• Plays a role in cancer progression by facilitating tumor angiogenesis and metastasis.
• Involved in fibrotic diseases where endothelial cells delaminate and contribute to myofibroblast pools.
• Required for hematopoietic stem cell emergence from hemogenic endothelium.
• Can be modeled in organ-on-a-chip systems for drug testing.
• Targeted by CRISPR screens to identify novel regulators [4,7].
• Dysregulation leads to vascular leak and hemorrhage.
• Provides a paradigm for studying cell adhesion dynamics in vivo [1,3].
What Happens During blood vessel endothelial cell delamination?
Initiation by Adhesion Downregulation
In simple terms: The first step is loosening the glue that holds endothelial cells together.
Delamination begins with the negative regulation of cell adhesion molecules, particularly VE-cadherin at adherens junctions. This downregulation is often triggered by signaling pathways such as TGF-beta and Notch, which activate transcription factors like Snail and Slug that repress cadherin expression [1,3]. The loss of adhesion allows cells to become motile and prepares them for detachment from the endothelial sheet.
Cytoskeletal Reorganization
In simple terms: The cell's internal skeleton rearranges to help it pull away from neighbors.
Following adhesion loss, the actin cytoskeleton undergoes dramatic reorganization. Rho GTPases (RhoA, Rac1, Cdc42) regulate the formation of stress fibers and lamellipodia, enabling the delaminating cell to generate traction forces. This cytoskeletal remodeling is essential for the physical separation of the cell from the endothelial monolayer.
Junctional Disassembly and Cell Detachment
In simple terms: The cell breaks free from its neighbors and moves away.
Adherens junctions and tight junctions are disassembled through endocytosis and degradation of junctional proteins. VE-cadherin is internalized, and the cell loses apical-basal polarity. The delaminating cell then extends protrusions and migrates away from the original sheet, a process observed in intussusceptive angiogenesis where endothelial cells form transluminal bridges.
Migration and Integration into New Structures
In simple terms: The detached cell travels to a new location and joins other cells.
After delamination, endothelial cells migrate along chemotactic gradients and can integrate into newly forming vessels or contribute to other tissues. In developmental hematopoiesis, dermomyotome-derived endothelial cells migrate to the dorsal aorta to support hematopoietic stem cell emergence. This step requires interactions with the extracellular matrix and other cell types.
Regulation by Hemodynamic Forces
In simple terms: Blood flow and mechanical forces influence whether cells delaminate.
Shear stress and mechanical forces from blood flow modulate endothelial delamination. Numerical modeling of endovenous ultrasound treatment shows that mechanical stress can impact the vascular wall and potentially trigger delamination. Organ-on-a-chip studies demonstrate that flow conditions affect endothelial tubule stability and delamination events.
Key Genes Involved in GO:0097497 blood vessel endothelial cell delamination
The following genes and proteins are central to the regulation and execution of blood vessel endothelial cell delamination, based on experimental evidence from developmental and disease models.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CDH5 (VE-cadherin) | Endothelial-specific adhesion molecule; its downregulation initiates delamination | Target for KO to block delamination; marker of endothelial integrity [1,3] |
| CDH2 (N-cadherin) | Adhesion molecule upregulated during EndMT; promotes migratory phenotype | Knockdown reduces delamination in fibrosis models |
| SNAI1 (Snail) | Transcription factor repressing E-cadherin and VE-cadherin; induces EndMT | Overexpression triggers delamination; KO prevents TGF-beta-induced EndMT [1,3] |
| SNAI2 (Slug) | Transcription factor involved in epithelial-mesenchymal transition | Regulates endothelial plasticity; potential therapeutic target |
| TWIST1 | Transcription factor promoting EndMT and cell migration | Knockout impairs delamination in developmental angiogenesis |
| RHOA | Small GTPase regulating actin cytoskeleton and contractility | Inhibitors block delamination; KO affects junctional stability |
| RAC1 | GTPase controlling lamellipodia formation and migration | Required for endothelial cell motility after delamination |
| CDC42 | GTPase regulating filopodia and cell polarity | Knockdown impairs directional migration of delaminated cells |
| TGFB1 | Cytokine inducing EndMT and delamination | Exogenous TGF-beta stimulates delamination in vitro |
| NOTCH1 | Receptor signaling that can promote or inhibit delamination depending on context | Modulates endothelial heterogeneity and delamination |
| VEGFA | Growth factor driving angiogenesis and endothelial migration | Stimulates delamination in sprouting angiogenesis |
| PECAM1 (CD31) | Endothelial junctional molecule; loss correlates with delamination | Marker for endothelial identity; KO affects junctional integrity |
| FLT1 (VEGFR1) | Receptor modulating VEGF signaling | Regulates delamination during developmental angiogenesis |
| KDR (VEGFR2) | Receptor mediating VEGF-induced migration | Inhibitors block delamination in organ-on-a-chip |
| ETS1 | Transcription factor regulating endothelial gene expression | Knockout alters delamination in vascular development |
| SOX17 | Transcription factor for endothelial and hemogenic endothelium | Required for delamination during hematopoietic emergence |
| GATA2 | Transcription factor in endothelial and hematopoietic lineages | Modulates delamination in dorsal aorta |
| RUNX1 | Transcription factor essential for hematopoietic stem cell emergence | Delamination of hemogenic endothelium requires RUNX1 |
How Is blood vessel endothelial cell delamination Regulated?
Blood vessel endothelial cell delamination is regulated by a complex interplay of signaling pathways, transcription factors, and mechanical forces. TGF-beta signaling activates SMAD-dependent transcription of SNAI1 and SNAI2, which repress VE-cadherin and promote delamination [1,3]. Notch signaling modulates endothelial heterogeneity and can either promote or inhibit delamination depending on context. VEGF signaling through VEGFR2 activates Rho GTPases and cytoskeletal remodeling necessary for cell detachment. Hemodynamic shear stress also influences delamination; numerical models show that mechanical forces during endovenous ultrasound treatment can impact the vascular wall. Additionally, organ-on-a-chip studies reveal that flow conditions affect endothelial tubule stability and delamination events. These regulatory inputs converge on adhesion complexes and the actin cytoskeleton to control whether an endothelial cell remains in the sheet or delaminates.
blood vessel endothelial cell delamination and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SNAI1 | Atherosclerosis, fibrosis | Endothelial-specific knockout mouse; TGF-beta treated HUVECs |
| CDH5 | Vascular leak, hemorrhage | Inducible VE-cadherin KO mouse; organ-on-a-chip |
| RHOA | Cancer, fibrosis | RhoA inhibitor-treated endothelial cells; CRISPR KO in zebrafish |
| TGFB1 | Atherosclerosis, EndMT | TGF-beta stimulated endothelial cells; SMAD reporter mice |
| RUNX1 | Hematopoietic defects | Runx1 knockout zebrafish; hemogenic endothelium differentiation |
Atherosclerosis and EndMT
In atherosclerosis, endothelial cells undergo EndMT, a process that shares molecular features with delamination. TGF-beta signaling induces SNAI1 and SNAI2, leading to loss of VE-cadherin and delamination of endothelial cells into the subendothelial space, where they contribute to plaque formation and fibrosis. Targeting delamination pathways may reduce atherosclerotic burden.
Cancer and Tumor Angiogenesis
Tumor angiogenesis relies on endothelial cell delamination to form new blood vessels that supply the tumor. Cytoskeletal reorganization and Rho GTPase signaling are hijacked by cancer cells to promote endothelial delamination and migration. Inhibiting delamination could normalize tumor vasculature and improve drug delivery.
Fibrotic Diseases
In fibrotic diseases such as pulmonary fibrosis and liver cirrhosis, endothelial cells delaminate and transition into myofibroblasts, contributing to excessive matrix deposition. This EndMT-like process is driven by TGF-beta and requires cytoskeletal changes. Blocking delamination may attenuate fibrosis.
Vascular Hemorrhage
Excessive endothelial delamination can compromise vessel integrity, leading to hemorrhage. Organ-on-a-chip studies using snake venoms show that endothelial tubule disruption and delamination correlate with hemorrhagic activity. Understanding delamination mechanisms can inform treatments for vascular leak syndromes.
From blood vessel endothelial cell delamination-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate endothelial delamination? | CRISPR knockout in endothelial cell lines or zebrafish [4,7] |
| Does a specific point mutation in gene Y affect delamination? | CRISPR point mutation knock-in in HUVECs or mouse models |
| How does gene Z overexpression affect delamination? | Lentiviral overexpression in endothelial cells; organ-on-a-chip |
| What is the role of gene W in developmental delamination? | Tagged knock-in for live imaging in zebrafish or mouse |
| Can a drug inhibit delamination? | Organ-on-a-chip with endothelial tubules and drug treatment |
| What are the transcriptomic changes during delamination? | RNA-seq of sorted delaminating cells from CRISPR models |
How to Study the blood vessel endothelial cell delamination Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Live imaging | Real-time delamination dynamics | Zebrafish, mouse, organ-on-a-chip [4,7] |
| Organ-on-a-chip | Endothelial tubule stability and delamination under flow | Drug testing, angiogenesis studies |
| RNA-seq | Transcriptomic changes during delamination | Identifying novel regulators |
| Proteomics | Protein expression and post-translational modifications | Adhesion complex analysis |
| Lineage tracing | Fate of delaminated cells | Developmental hematopoiesis |
| CRISPR screens | Genes required for delamination | Functional genomics |
| Numerical modeling | Mechanical stress on vascular wall | Endovenous ultrasound treatment |
| Immunofluorescence | Localization of junctional and cytoskeletal proteins | VE-cadherin internalization [1,3] |
Live Imaging of Endothelial Delamination
Live imaging using fluorescently tagged endothelial cells (e.g., VE-cadherin-GFP) allows real-time visualization of delamination events in zebrafish, mouse, and organ-on-a-chip systems [4,7]. This method reveals the dynamics of junctional disassembly and cell migration.
Organ-on-a-Chip Models
Microfluidic organ-on-a-chip platforms reconstitute endothelial tubules under flow, enabling precise control of mechanical and biochemical cues. These models have been used to study intussusceptive angiogenesis and delamination induced by snake venoms [4,5].
Transcriptomic and Proteomic Profiling
RNA-seq and proteomics of endothelial cells undergoing delamination identify differentially expressed genes and pathways. For example, TGF-beta-treated endothelial cells show upregulation of SNAI1 and downregulation of CDH5 [1,3].
Genetic Lineage Tracing
Lineage tracing using Cre-lox systems in mice (e.g., Tie2-Cre) marks endothelial cells and their progeny, allowing tracking of delaminated cells into other tissues. This approach has been used to study hemogenic endothelium delamination.
How CRISPR Can Be Used to Study GO:0097497 blood vessel endothelial cell delamination
Knockout
CRISPR knockout of candidate genes (e.g., CDH5, SNAI1, RHOA) in endothelial cells or animal models can determine whether they are required for delamination. For example, VE-cadherin knockout leads to spontaneous delamination and vascular leak [1,3]. Zebrafish runx1 knockouts fail to delaminate hemogenic endothelium.
Point Mutation
CRISPR point mutation knock-in can model specific amino acid changes in adhesion molecules or signaling proteins to test their role in delamination. For instance, mutating phosphorylation sites in VE-cadherin can reveal their importance in junctional disassembly.
Knock-in
Tagged knock-in (e.g., GFP or luciferase) allows live imaging and tracking of delaminating cells. Knock-in of reporter genes under endogenous promoters (e.g., SNAI1-GFP) enables visualization of transcriptional activation during delamination [4,7].
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can drive genes like SNAI1 or TWIST1 to induce delamination. This approach is useful for studying gain-of-function effects and identifying downstream targets [1,3].
How EDITGENE Supports blood vessel endothelial cell delamination Research
Researchers studying blood vessel endothelial cell delamination-related genes often need to determine whether a candidate gene is causally involved in the process or merely correlated with it. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation in endothelial cells and animal models, accelerating discovery in vascular biology.
Contact EDITGENE today to design your custom CRISPR model for blood vessel endothelial cell delamination research.
Frequently Asked Questions About blood vessel endothelial cell delamination
What is blood vessel endothelial cell delamination?
It is the process defined by GO:0097497 where negative regulation of cell adhesion causes blood vessel endothelial cells to split off from an existing endothelial sheet.
What genes are involved in blood vessel endothelial cell delamination?
Key genes include CDH5 (VE-cadherin), SNAI1, SNAI2, TWIST1, RHOA, RAC1, CDC42, TGFB1, and RUNX1 [1,3,7].
How is endothelial delamination studied?
It is studied using live imaging, organ-on-a-chip models, RNA-seq, and CRISPR screens [4,5,7].
What diseases are associated with endothelial delamination?
Atherosclerosis, cancer, fibrosis, and vascular hemorrhage are linked to dysregulated delamination [1,3,5].
What is the role of VE-cadherin in delamination?
VE-cadherin downregulation is a key step initiating delamination; its loss allows endothelial cells to detach [1,3].
Can CRISPR be used to study endothelial delamination?
Yes, CRISPR knockout, knock-in, and overexpression models enable precise genetic manipulation to test gene function [4,7].
What is the difference between delamination and EndMT?
Delamination is the physical detachment of endothelial cells, while EndMT is a broader phenotypic transition that can include delamination [1,3].
Which signaling pathways regulate endothelial delamination?
TGF-beta, Notch, and VEGF signaling pathways regulate delamination through transcription factors and cytoskeletal changes [1,4,5].
What model organisms are used to study delamination?
Zebrafish, mice, and organ-on-a-chip systems are commonly used [4,5,7].
How can I model endothelial delamination in vitro?
Organ-on-a-chip platforms with endothelial tubules under flow, or TGF-beta-treated endothelial monolayers, can induce delamination [4,5].
Conclusion
Blood vessel endothelial cell delamination (GO:0097497) is a critical biological process that controls endothelial cell detachment from existing sheets, with profound implications for vascular development, homeostasis, and disease. Advances in organ-on-a-chip technology, live imaging, and CRISPR-based genetic models have illuminated the molecular players and regulatory mechanisms. Continued research will uncover new therapeutic targets for atherosclerosis, cancer, and fibrotic diseases.
References
- 1. Souilhol C et al.. 2018. Endothelial-mesenchymal transition in atherosclerosis.. Cardiovasc Res 114(4):565-577 PMID: 29309526
- 3. Ciszewski WM et al.. 2021. Cytoskeleton Reorganization in EndMT-The Role in Cancer and Fibrotic Diseases.. Int J Mol Sci 22(21) PMID: 34769036
- 4. Staples SCR et al.. 2025. Intussusceptive angiogenesis-on-a-chip: Evidence for transluminal vascular bridging by endothelial delamination.. Proc Natl Acad Sci U S A 122(16):e2423700122 PMID: 40244661
- 5. Bittenbinder MA et al.. 2024. Using organ-on-a-chip technology to study haemorrhagic activities of snake venoms on endothelial tubules.. Sci Rep 14(1):11157 PMID: 38834598
- 7. Sahai-Hernandez P et al.. 2023. Dermomyotome-derived endothelial cells migrate to the dorsal aorta to support hematopoietic stem cell emergence.. Elife 12 PMID: 37695317
- 8. Borde AS et al.. 2022. Numerical modeling of the impact on the vascular wall during endovenous ultrasound treatment.. Med Eng Phys 100:103745 PMID: 35144733
